SCHISTOSOME HOST/INTERACTIVE SURFACE MEMBRANE PROTEINS
血吸虫宿主/相互作用表面膜蛋白
基本信息
- 批准号:2064495
- 负责人:
- 金额:$ 22.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-09-30 至 1998-07-31
- 项目状态:已结题
- 来源:
- 关键词:Schistosoma mansoni antibody specificity antigen antibody reaction cellular immunity complementary DNA drug design /synthesis /production drug screening /evaluation enzyme linked immunosorbent assay flow cytometry gel filtration chromatography high performance liquid chromatography host organism interaction humoral immunity immunoaffinity chromatography immunofluorescence technique ion exchange chromatography laboratory mouse membrane proteins passive immunization radionuclides recombinant proteins schistosomiasis vaccines western blottings
项目摘要
Schistosomes are extracellular blood flukes that can survive for many
years within the human vascular system. Since the worms interact closely
with their host, performing functions such as nutrient uptake and
attachment that are normally performed by integral surface membrane
proteins, the parasites must have developed mechanisms for avoiding
immune attack directed at these proteins. Our goal is to determine
whether these functional, host-exposed, schistosome membrane proteins can
be effective targets of a schistosomiasis vaccine. If successful, this
novel vaccination strategy should also be effective against other
diseases caused by helminth parasites.
Towards our goal, we have obtained several full-length Schistosoma
mansoni cDNA clones, three of which encode surface membrane proteins that
we have shown to be present at the host/parasite interface in living
worms. These include a glucose transporter, an amino acid permease
homologue and the surface antigen, SM23. All have been expressed to high
levels within recombinant insect cells. In this application, we propose
to focus our efforts on the three bona fide schistosome host-interactive
membrane proteins (HIMPs) and perform the definitive studies that win
ascertain whether HIMPs can be targets of an effective schistosomiasis
vaccine. We will use both conformationally native, recombinant protein
and naked DNA expression plasmids as immunogens to induce cellular and/or
humoral immune responses against host-exposed epitopes on the HIMPs.
Successfully immunized mice will be tested for their ability to resist
schistosome infection. A library of recombinant antibodies (rAbs) will
be generated from the spleens of successfully immunized mice and screened
for clones that display surface epitope recognition. Purified rAbs from
positive clones will be tested for their ability to passively transfer
protection against cercariaI infection. Host-exposed epitopes will be
determined and used to design improved vaccine candidates.
血吸虫是细胞外的血吸虫,
在人体血管系统中的时间。由于蠕虫之间
与其宿主,执行功能,如营养吸收,
通常由整体表面膜进行的附着
蛋白质,寄生虫必须发展机制,以避免
针对这些蛋白质的免疫攻击。我们的目标是确定
这些功能性的、暴露于宿主的、多体的膜蛋白是否可以
成为血吸虫病疫苗的有效靶点如果成功,这
新的疫苗接种策略也应该对其他
由蠕虫寄生虫引起的疾病。
为了实现我们的目标,我们已经获得了几个全长血吸虫
mansoni cDNA克隆,其中三个编码表面膜蛋白,
我们已经证明,在生活中,
蠕虫包括葡萄糖转运蛋白,氨基酸通透酶
同源物和表面抗原SM 23。所有这些都被表达为高
重组昆虫细胞内的水平。在本申请中,我们提出
把我们的努力集中在三个真正的令人讨厌的主机互动
膜蛋白(HIMPs),并进行决定性的研究,
确定HIMPs是否可以成为有效血吸虫病治疗的靶点
疫苗我们将使用构象天然的重组蛋白
和裸DNA表达质粒作为免疫原诱导细胞和/或
针对HIMP上的宿主暴露表位的体液免疫应答。
成功免疫的小鼠将接受抵抗能力测试
可怕的感染。重组抗体(rAb)文库将
从成功免疫的小鼠的脾脏产生并筛选
用于显示表面表位识别的克隆。纯化的rAbs来自
将测试阳性克隆的被动转移能力,
防止尾蚴感染。宿主暴露的表位将是
确定并用于设计改进的候选疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Bix Shoemaker其他文献
Charles Bix Shoemaker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Bix Shoemaker', 18)}}的其他基金
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes
RNA 编码的基于纳米抗体的免疫疗法,靶向与宿主相互作用的重要血吸虫胞外酶
- 批准号:
10571150 - 财政年份:2022
- 资助金额:
$ 22.21万 - 项目类别:
Immune-based therapy against STEC intoxication and HUS
针对 STEC 中毒和 HUS 的免疫疗法
- 批准号:
10517289 - 财政年份:2020
- 资助金额:
$ 22.21万 - 项目类别:
Immune-based therapy against STEC intoxication and HUS
针对 STEC 中毒和 HUS 的免疫疗法
- 批准号:
10305597 - 财政年份:2020
- 资助金额:
$ 22.21万 - 项目类别:
Immune-based therapy against STEC intoxication and HUS
针对 STEC 中毒和 HUS 的免疫疗法
- 批准号:
10095464 - 财政年份:2020
- 资助金额:
$ 22.21万 - 项目类别:
Tagged binding agents as improved anti-toxin therapeutics
标记结合剂作为改进的抗毒素疗法
- 批准号:
8233432 - 财政年份:2011
- 资助金额:
$ 22.21万 - 项目类别:
Reversing botulism with agents that accelerate intraneuronal toxin degradation
使用加速神经元内毒素降解的药物逆转肉毒杆菌中毒
- 批准号:
8026020 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Reversing botulism with agents that accelerate intraneuronal toxin degradation
使用加速神经元内毒素降解的药物逆转肉毒杆菌中毒
- 批准号:
7875009 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Tagged binding agents as improved anti-toxin therapeutics
标记结合剂作为改进的抗毒素疗法
- 批准号:
7669763 - 财政年份:2009
- 资助金额:
$ 22.21万 - 项目类别:
In vivo panning for schistosome protective epitopes
体内淘选血吸虫保护性表位
- 批准号:
6814836 - 财政年份:2004
- 资助金额:
$ 22.21万 - 项目类别:
In vivo panning for schistosome protective epitopes
体内淘选血吸虫保护性表位
- 批准号:
6919822 - 财政年份:2004
- 资助金额:
$ 22.21万 - 项目类别:
相似海外基金
Optimising antibody specificity and efficacy through Fc engineering
通过 Fc 工程优化抗体特异性和功效
- 批准号:
BB/N503927/1 - 财政年份:2015
- 资助金额:
$ 22.21万 - 项目类别:
Training Grant
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8136201 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
7994664 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8324720 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8537214 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8328875 - 财政年份:2010
- 资助金额:
$ 22.21万 - 项目类别:
Quantitative Serum Antibody Specificity Screening in Celiac Disease
乳糜泻血清抗体特异性定量筛查
- 批准号:
7531456 - 财政年份:2008
- 资助金额:
$ 22.21万 - 项目类别:
Quantitative Serum Antibody Specificity Screening in Celiac Disease
乳糜泻血清抗体特异性定量筛查
- 批准号:
7673756 - 财政年份:2008
- 资助金额:
$ 22.21万 - 项目类别:
CARBOHYDRATES AND GLYCOPROTEINS IN ANTIBODY SPECIFICITY AND EFFECTOR MECHANISMS
抗体特异性和效应机制中的碳水化合物和糖蛋白
- 批准号:
6978238 - 财政年份:2004
- 资助金额:
$ 22.21万 - 项目类别:
HLA-D antigens, T cell epitopes and antibody specificity in SLE
SLE 中的 HLA-D 抗原、T 细胞表位和抗体特异性
- 批准号:
6663942 - 财政年份:2002
- 资助金额:
$ 22.21万 - 项目类别: